Goldline Pharmaceutical
Table of Contents
- 01 IPO Description
- 02 IPO Parameters
- 03 IPO Roadmap
- 04 GMP History
- 05Goldline Pharmaceutical IPO Market Lot
- 06 Goldline Pharmaceutical IPO Details
- 07 Goldline Pharmaceutical IPO Reservation
- 08 Goldline Pharmaceutical IPO Anchor Investors
- 09 Goldline Pharmaceutical IPO Dates
- 10 Goldline Pharmaceutical IPO Promoters & Holding Pattern
- 11 Goldline Pharmaceutical IPO – Objects of the Issue
- 12 About Goldline Pharmaceutical IPO
- 13 Goldline Pharmaceutical IPO Company Financial Report
- 14 Goldline Pharmaceutical IPO Valuation – FY2025
- 15 Goldline Pharmaceutical IPO Peer Group Comparison
- 16 IPO Lead Managers aka Merchant Bankers
IPO PARAMETERS
IPO ROADMAP
Grey Market Premium HISTORY
| Date | GMP (₹) | Daily Change | Gain (%) |
|---|---|---|---|
| 13 May 2026 | ₹18.00 | +₹1.00 | 41.86% |
| 12 May 2026 | ₹17.00 | - | 39.53% |
Goldline Pharmaceutical IPO MARKET LOT
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 | 6,000 | ₹258,000 |
| Retail Maximum | 2 | 6,000 | ₹258,000 |
| S-HNI Minimum | 3 | 9,000 | ₹387,000 |
| S-HNI Maximum | 7 | 21,000 | ₹903,000 |
| B-HNI Minimum | 8 | 24,000 | ₹1,032,000 |
Goldline Pharmaceutical IPO DETAILS
| IPO Open Date | May 12, 2026 |
|---|---|
| IPO Close Date | May 14, 2026 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹41 to ₹43 Per Share |
| Issue Size | Approx ₹12 Crores |
| Fresh Issue | Approx ₹12 Crores |
| Issue Type | Book build Issue |
| IPO Listing | BSE SME |
Goldline Pharmaceutical IPO RESERVATION
| Investor Category | Shares Offered | Shares (%) |
|---|---|---|
| Anchor Investor | 7,32,000 | 27.11% |
| QIB (Ex. Anchor) | 5,40,000 | 20.00% |
| NII | 3,90,000 | 14.44% |
| Retail | 9,00,000 | 33.33% |
Goldline Pharmaceutical IPO Anchor INVESTORS
| Anchor Bidding Date | May 11, 2026 |
|---|---|
| Shares Offered | 7,32,000 |
| Anchor Size | — |
| Lock-in Period (50% Shares - 30 Days) | 2026 |
| Lock-in Period (50% Shares - 90 Days) | 2026 |
Goldline Pharmaceutical IPO DATES
| IPO Open Date | May 12, 2026 |
|---|---|
| IPO Close Date | May 14, 2026 |
| Basis of Allotment | May 15, 2026 |
| Refunds | May 18, 2026 |
| Credit to Demat Account | May 18, 2026 |
| IPO Listing Date | May 19, 2026 |
| Bidding Cut-off Time | May 14, 2026 – 5 PM |
Goldline Pharmaceutical IPO Promoters & Holding PATTERN
| Particular | Shares | % Share |
|---|---|---|
| Promoter Holding Pre Issue | 69,00,000 | 79.70% |
| Promoter Holding Post Issue | 96,00,000 | — |
| Promoters |
|---|
| Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal |
Goldline Pharmaceutical IPO – Objects of the ISSUE
| Purpose | Amount (₹ Cr.) |
|---|---|
| Prepayment / Repayment of Borrowings | 8.90 |
| General Corporate Purpose | — |
About Goldline Pharmaceutical IPO
Goldline Pharmaceuticals is one of the leading companies involved in the marketing of pharmaceutical products under the name Goldline. Its products are divided into 5 segments: 1. Goldline Pharma, which includes specialities like Physicians, Orthopedics, ENT, Chest Physicians, General and Speciality Surgery, Gastroenterology, Neurology, and Urology, 2. Goldline Cardinal, which includes specialities like Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians, 3. Goldline Ayushman, which includes Pediatricians, Child Specialists, Neonatologists, and General Practitioners, 4. Goldline InLife, which includes Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians, and 5. Goldline Wellness, which includes cancer therapy.
The company sells its products across various states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. Moreover, all the products of the firm are sold and distributed under the brand Goldline.
Goldline Pharmaceutical IPO Company Financial REPORT
| Period Ended | Revenue (₹ Cr.) | Expense (₹ Cr.) | PAT (₹ Cr.) | Assets (₹ Cr.) |
|---|---|---|---|---|
| 2023 | 19.85 | 19.45 | 0.26 | 19.39 |
| 2024 | 23.57 | 21.04 | 1.81 | 22.93 |
| 2025 | 28.06 | 24.20 | 2.83 | 26.28 |
| Dec 2025 | 21.41 | 18.40 | 2.22 | 27.40 |
Goldline Pharmaceutical IPO Valuation – FY2025
| KPI | Values |
|---|---|
| ROE | 35.84% |
| ROCE | 38.46% |
| EBITDA Margin | 20.79% |
| PAT Margin | 10.10% |
| Debt to Equity | 1.50 |
| EPS (Basic) | ₹4.10 |
| P/E Ratio | N/A |
| RoNW | 27.37% |
| NAV | ₹12.38 |
Goldline Pharmaceutical IPO Peer Group COMPARISON
| Company | EPS | P/E Ratio | RoNW % | NAV | Income (₹ Cr.) |
|---|---|---|---|---|---|
| Mono Pharmacare Limited | 1.75 | 7.57 | 9.90% | 17.66 | 168.34 |
| Chandra Bhagat Pharma Limited | 1.14 | 28.94 | 2.86% | 39.72 | 86.72 |
IPO Lead Managers aka Merchant BANKERS
IPO Lead Managers aka Merchant Bankers
- Cumulative Capital Pvt. Ltd.